M&A - RECURSION PHARMACEUTICALS, INC.

Form Type: 10-K

Filing Date: 2025-02-28

Corporate Action: Merger

Type: Update

Accession Number: 000160183025000035

Filing Summary: Recursion Pharmaceuticals, Inc. has undertaken the largest merger in the TechBio sector to date, combining with Exscientia to form a comprehensive AI-driven drug discovery platform. This merger aims to leverage both companies' strengths, enhancing drug discovery efficiency from initial insights through to clinical development. The collaboration intends to use advanced AI models integrated with biological data to streamline drug development processes. Recursion anticipates around 10 key clinical milestones over the next 18 months, including potential breakthroughs in various cancer treatments, such as the REC-1245 and REC-617 programs. The company continues to explore significant partnerships with major firms like Roche, Genentech, Sanofi, and Merck, highlighting over $450 million received in collaboration payments. Recursion projects further milestone payments that could reach up to $20 billion, signaling ambitious goals for AI integration in drug discovery moving forward.

Document Link: View Document